Third Rock seeds cell therapy startup with $95M in bid to cure MS
In 2018, former Biogen executives Samantha Singer and Richard Ransohoff were working with Third Rock on a new way to treat autoimmune diseases when one of the VC’s partners asked what Ransohoff thought of a wildly different approach to tackling those bedeviling disorders.
Third Rock wanted to build a company that would turn a protective class of immune cells called regulatory T cells into therapies, and another team had spent the last year and a half trying to find the best condition it would work for. Finally, they settled on multiple sclerosis, a disease Ransohoff had studied for three decades as an academic. They wanted his opinion: What do you think?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
